Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 10;10(24):e021323. doi: 10.1161/JAHA.121.021323

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

A, Antiarrhythmic drug utilization decreased between discharge (blue) and 12 months (yellow) among patient subgroups. B, Kaplan‐Meier estimate of freedom from reablation over 12 months is displayed. Persistent atrial fibrillation (AF), but not heart failure (HF) status (P=0.439), predicted reablation (P=0.001) over follow‐up. Kaplan–Meier estimates of (C) freedom from all‐cause and (D) cardiovascular‐related rehospitalization over 12‐month follow‐up are presented. HF predicted both all‐cause (P<0.001) and cardiovascular‐related (P<0.001) rehospitalization. Persistent AF did not predict all‐cause hospitalization (P=0.179) but did predict cardiovascular‐related rehospitalization (P=0.032) over follow‐up. AAD indicates antiarrhythmic drug; PAF, paroxysmal atrial fibrillation; and PsAF, persistent atrial fibrillation.